Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics

ImmunoPrecise Antibodies is a full-service therapeutic antibody discovery and development company with decades of experience and global coverage, with locations in Europe, Canada and the US. This article will present a case study utilizing robust, target-enrichment-based antibody discovery technologies that allow accelerated, high-throughput identification of diversified pools of lead antibody candidates, an essential first step for a successful therapeutic program.

Please enter your email to access content Read now